Cents and Sensibility - Kimberly and Friends' Consortium Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dustin who wrote (39352)	12/6/1999 6:37:00 PM
From: EtTuBrute	Read Replies (1) of 108040

Here is official CYGN news. CYGN should fly tomorrow: Monday December 6, 6:29 pm Eastern Time FDA panel backs Cygnus diabetes glucose monitor GAITHERSBURG, Md., Dec 6 (Reuters) - Federal advisers on Monday backed a watch-like device by Cygnus Inc. (NasdaqNM:CYGN - news) designed to help diabetics keep better track of changes in their blood sugar. A Food and Drug Administration advisory panel voted unanimously that the GlucoWatch was safe and effective for sale in the United States. The committee's support is important because the FDA usually follows the advice of its panels. Cygnus said the device could provide painless measurements of blood sugar, or glucose, every 20 minutes for up to 12 hours. Better glucose information can help patients and their doctors adjust treatments to improve management of the disease. Nearly 16 million Americans have diabetes, which can lead to serious complications such as blindness, limb loss and kidney damage. Cygnus, based in Redwood City, Calif., recently announced it would sell most of the assets from its drug delivery business to a Johnson & Johnson unit and focus on developing the GlucoWatch.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next